Modification of incident cancer risk with changes in metabolic syndrome status: A prospective cohort study in Taiwan

Purpose: We aimed to investigate the effect of altered metabolic syndrome (MetS) status on cancer risk. Methods: From 2002 through 2008 of the Taiwan MJ cohort, there were 111,616 adults who had repeated MetS measurements performed 3.3 years apart and were followed up for cancer incidence over 11.8 years. Cancer was confirmed based on histopathological reports. Results: Participants were categorized as MetS-free (n = 80,409; no MetS at the first or last health screening), MetS-developed (n = 9833; MetS absence at the first screening and presence at the last screening), MetSrecovered (n = 8958; MetS presence at the first screening and absence at the last screening), and MetSpersisted (n = 12,416; MetS presence at the first and last screenings). We used the Fine -Gray sub-distribution method, with death as competing risk, to determine the association between MetS changes and incident cancer risk. During 1320,796 person-years of follow-up, 5862 individuals developed cancer. The incidence rate of cancer per 1000 person-years was 3.89 in the MetS-free, 5.26 in MetS-developed, 4.61 in MetS-recovered, and 7.33 in MetS-persisted groups (P < .001). Compared with the MetS-free group, MetS-persisted individuals had a higher risk of incident cancer. Conclusions: Persistent MetS was found to be associated with a high risk of incident cancer.